Navigation Links
Testosterone Lawsuit Alleges AndroDerm Patch Caused Death of Virginia Man, Bernstein Liebhard LLP Reports
Date:8/13/2014

New York, New York (PRWEB) August 13, 2014

The family of a deceased Virginia man has filed a testosterone lawsuit (http://www.drugbot.com/testosterone/lawsuit/) that accuses the manufacturer of the AndroDerm Patch of failing to warn patients of its alleged association with serious cardiovascular problems, including heart attacks and strokes. According to the complaint, which was filed in the U.S. District Court for the District of Utah on August 1st, the family claims that his use of the AndroDerm Patch from October 2005 to February 2008, and again from July 2008 to May 2012 led to a diagnosis of deep vein thrombosis in October 2012. The lawsuit also claims that the low testosterone therapy caused the decedent to suffer strokes in June and July 2012, which ultimately led to his death in August 2012. (Case 2:14-cv-00567-DBP)

“Our Firm has heard from a number of men who used low testosterone therapies, all of whom claim to have suffered serious cardiovascular events that echo the injuries cited in this complaint,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating testosterone lawsuits on behalf of men who were allegedly harmed by these medications.

Low Testosterone Therapy Litigation
Court documents indicate that the litigation involving low testosterone therapy has been growing since January 2014, when U.S. Food & Drug Administration (FDA) announced that it was investigating cardiovascular risks associated with these drugs. The agency’s review was prompted by two studies which indicated that older men, as well as those with pre-existing heart disease, were more likely to suffer heart attacks, strokes or death if they were using testosterone medications.

Last month, the FDA announced that it will convene a joint meeting of the Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on September 17, 2014, at which time the members will be asked to make recommendations pertaining to the cardiovascular side effects associated with prescription testosterone treatments. The Committees will also address what factors should be considered when deciding whether men need to use low testosterone therapy.*

According to court documents, more than 150 testosterone lawsuits have been filed on behalf of U.S. plaintiffs in a multidistrict litigation underway in U.S. District Court, Northern District of Illinois. Like the case pending in Utah, plaintiffs in these lawsuits also accuse the manufacturers of low testosterone therapies of failing to warn doctors and patients about their potential to cause serious heart problems. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

Men who experienced life-threatening cardiovascular events allegedly due to AndroDerm or other low testosterone therapies may be entitled to compensation for their injury-related damages. To learn more, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.

*fda.gov/AdvisoryCommittees/Calendar/ucm404905.htm, FDA, July 17, 2014
About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:

Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.drugbot.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/testosterone-lawsuit/androderm-lawsuit/prweb12092935.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Partner Kristine Kraft Appointed to the Plaintiffs’ Steering Committee (PSC) in Federal Testosterone Replacement Therapy MDL, Schlichter, Bogard & Denton, LLP Reports
2. Testosterone in healthy men increases their brains response to threat
3. FDA Seeks Answers As Testosterone Lawsuits Mount Against "Low T" Drug Makers
4. Testosterone Lawsuit News: Bernstein Liebhard LLP Notes Report Indicating That More Men are Seeking Prescription Supplements
5. Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL
6. Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone
7. Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports
8. As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics
9. FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward
10. New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue
11. Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2020)... LAUREL, N.J. (PRWEB) , ... May 27, 2020 ... ... contract manufacturer, announces that it is now manufacturing face shields to be ... novel coronavirus that causes COVID-19. These face shields are single use, made to ...
(Date:5/27/2020)... ... May 27, 2020 , ... ... of Washington Professor of Bioengineering, Founder & Editor of scientific journal WATER, ... ( https://www.amazon.com/Fourth-Phase-Water-Beyond-Liquid-ebook/dp/B00N2ASKF2 ) , https://www.voiceamerica.com/episode/123059/the-fourth-phase-of-water , * , During ...
(Date:5/26/2020)... ... , ... Today TRC Companies (“ TRC ”) announced the release of its ... owners and leaders assess whether their organizations are prepared to move forward as the ... intended to assist business leaders evaluate their readiness relative to CDC guidance and provides ...
(Date:5/25/2020)... ... ... Winemaker Grant Long Jr. is introducing three Toilet Paper Reserve wines. “These are ... complicated times,” he said, in announcing the new wines. The wines are 2019 Chardonnay ... Wine Blend are sourced in the Napa Valley; the Grenache comes from the El ...
(Date:5/21/2020)... Minn. (PRWEB) , ... May 21, 2020 , ... ... medical device manufacturer, announces its first milestone to deliver over one million FDA-compliant ... eight weeks. Summit Medical Face Shields meet the critical need for personal protective ...
Breaking Medicine News(10 mins):
(Date:5/21/2020)... ... May 21, 2020 , ... ... needs in the field of urology, today announced that Naveen Divakaruni, D.O., Advocate ... Excellence. The designation recognizes that Dr. Divakaruni has achieved a high level of ...
(Date:5/21/2020)... ... ... Labyrinthe Labs has announced the launch of its brand new and ground-breaking ... for fast-action relief of joint and muscle soreness, Lefa is botanically powered by a ... and muscles. , According to the National Institutes of Health , approximately ...
(Date:5/17/2020)... ... 2020 , ... The Sea Cucumber-derived triterpenoid glycoside Frondoside A, which has been ... the Sea Cucumber in a proprietary process to give SeaCare Dietary Supplement ... and time again: “You get what you pay for.” It is usually in reference ...
Breaking Medicine Technology: